New American Joint Commission on Cancer staging system for melanoma: prognostic impact and future directions.
Accurate melanoma staging is critical in establishing management strategies and estimating disease relapse. Combined with assessment of comorbidities and understanding treatment toxicities, risk assessment is central to offering appropriate surgical or systemic therapies. The American Joint Commission on Cancer (AJCC) melanoma staging system provides survival estimates within anatomically defined disease categories. Newer prognostic factors and methods of prognostic analyses can augment predictions for the presence of micro-metastatic disease and further define the risk for relapse. This article highlights relevant changes, evidence supporting future incorporation of more recently defined prognostic variables, novel approaches used as adjuncts to the current staging system, and future directions of the AJCC staging committee.
Ross
Merrick I
MI
Department of Surgical Oncology, University of Texas M. D. Anderson Cancer Center, 1400 Holcombe Boulevard, Unit #444, Houston, TX 77030, USA. mross@mdanderson.org
D026683:Advisory Committees; D014408:Biomarkers, Tumor; D006801:Humans; D008545:Melanoma / Q000175:diagnosis / Q000401:mortality / Q000473:pathology*; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000473:pathology; D009367:Neoplasm Staging; D010338:Pathology, Clinical / Q000379:methods*; D011379:Prognosis; D018570:Risk Assessment; D012878:Skin Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000473:pathology*; D014481:United States
D014408:Biomarkers, Tumor